Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02359968
Other study ID # PROTECT-1402
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 26, 2015
Est. completion date February 9, 2024

Study information

Verified date February 2024
Source Centre Oscar Lambret
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX. It is a combination of three drugs administered intravenously: fluorouracil, oxaliplatin and folinic acid. This is the standard treatment. Another protocol of chemotherapy is widely used by certain European and American teams, due to promising results : a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT). At present, no clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments.


Description:

There is no standard preoperative (neoadjuvant) chemoradiation (NCRT) regimen for resectable esophageal cancer, because most if all trials failed to show any survival advantage favoring pCRT when compared to surgery only. This failure had been related to the lack of power of some trials, as well as the ability of chemoradiation to potentiate post-operative morbidity (including mortality), and therefore hampering the accrual of its own survival benefit. Hopefully, meta-analyses showed that NCRT increases survival when compared to surgery only. However, in the clinical practice, this does not make easier the choice of the best NCRT treatment. It appeared that the radiation regimen that were used in each randomized trials were heterogeneous with respect with dose, fraction, length of treatment, fields, dosimetry planning, and quality control. This applies also to chemotherapy with respect with the kind of cytotoxics that were used (including number of drugs), as well as dosage, and the number of cycles, although most of the time cytotoxics were fluorouracil and cisplatin. Dutch colleagues recently showed that NCRT with weekly carboplatin and paclitaxel increase survival, without increasing postoperative mortality. Of note, most tumors in this trial arose from the lower third of the esophagus and esogastric junction and these habitually correlate with less postoperative morbidity compared to upper third tumors. Moreover, the lung volume spared from radiation was greater in junctional tumors than in upper third cancers - a critical point in the development of radiation-induced pneumonitis and subsequent postoperative mortality. It is difficult to understand how this taxane-based chemotherapy is active, as it did not make better that fluorouracil-based regimen in non-operable patients, and as NCRT with taxanes makes radiation-induced pneumonitis more likely. The favorable impact of this NCRT may lie on its radiation regimen. A moderate total dose of radiation, smaller radial margins than in other trials and modern dosimetry with 3D-planning all improve the safety of treatment and of subsequent surgery. Finally, the favorable impact of the Dutch NCRT regimen may lies on the fact that it does not include cisplatin, a compound which has been found related to the occurrence of more sudden deaths than a non cisplatin-based regimen such as the FOLFOX combination (fluorouracil, oxaliplatin, folinic acid) in the setting of definitive chemoradiotherapy. Our aim is to evaluate the short-term benefit (complete resection rate) and safety (severe postoperative rate) of 2 preoperative regimen, (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid), combined to the Dutch radiation backbone, in operable esophageal and junctional (Siewert I-II) cancer. The present trial offers the unique opportunity to compare two therapeutic strategies that have already been shown to be efficient in large randomized controlled trials offering level-1 evidence.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date February 9, 2024
Est. primary completion date January 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II) - Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial) - Patient who present with: - stage IIA (T3N0M0) - stage IIB (T1 N1 M0 or T2 N1 M0), - stage III (T3 N1 M0 or T4 N0 N1 M0) tumors - ECOG performance status 0, 1 or 2 - Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin - Age = 18 - Peripheral neuropathy = NCI-CTC grade 1 - Adequate bone marrow reserve, normal renal and liver functions: - Neutrophil count = 1500/mm3 - Platelet count = 100 000/mm3 - Hemoglobin = 10 g/dl (after transfusion, if necessary) - Creatinin < 15mg/L - Clearance of creatinin (Cockcroft formulae) = 60 ml/mn - Prothrombin time = 60% - ASAT-ALAT =2.5 x ULN - Total bilirubin < 1.5 x ULN - Albumin greater the lower limit of normal - Start of treatment within 28 days after randomization - Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential - Patient covered by government health insurance - Patient who provide a signed written informed consent form Exclusion Criteria: - Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV - Patient who present with common contraindications for surgery related to patient status - Patient who present with common contraindications for surgery related to disease extension - Patient who present with common contraindication to radiochemotherapy with either fluorouracile-cisplatin or with paclitaxel-carboplatin

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOX
radiochemotherapy before surgery
CarboP-pacliT
radiochemotherapy before surgery

Locations

Country Name City State
France ICO Paul Papin Angers
France CHU Bordeaux Bordeaux
France Centre Oscar Lambret Lille
France University Hospital of Lille Lille
France Hôpital La Timone Marseille
France Hôpital Nord Marseille
France ICM - Val d'Aurelle Montpellier
France CH Lyon sud Pierre-Bénite
France Centre Eugène Marquis Rennes
France ICO René Gauducheau Saint-Herblain

Sponsors (2)

Lead Sponsor Collaborator
Centre Oscar Lambret National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other DVH (CoDose-Volume-Histogram (DVH) and postoperative respiratory morbidity up to 30 days after the beginning of radiotherapy
Other Comparison of both arms in terms of safety and efficacy Evaluation of preoperative mortality (grade 5) rate according to NCI-CTCAE v4.0 criteria, pre-operative morbidities according to NCI-CTCAE v4.0 criteria, post-operative morbidities occurring in the 30 days after surgery with the main post-operative complication graded according to Clavien-Dindo, post-operative morbidities occurring more than 30 days after surgery graded according to NCI-CTCAE V4.0, postoperative respiratory morbidity rate according to the Clavien-Dindo classification.
Evaluation of overall survival and disease-free survivalusing Kaplan-Meier method, complete pathological response (ypCR) rate
From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Other Net treatment benefit estimation To estimate the net treatment benefit, combining efficacy and safety endpoints, using the Generalized Pairwise Comparisons Method - GPC method (Buyse, 2010) From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Other Prognostic factor and treatment effect controlling for possible confounding factors To identify prognostic factors associated to disease-free survival, and evaluate the treatment effect controlling for possible confounding factors. Following factors will be studied: pre-therapeutic stage (II versus III), pre-therapeutic N (positive versus negative), post-surgery stage (ypT0N0 versus other), TRG (1-2 versus other) and resection (R0 versus other). From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
Primary Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade = 3) postoperative morbidity/mortality according to the Clavien-Dindo classification Complete resection rate (R0, that is "complete removal of all tumor with microscopic examination of margins showing no tumor cells") AND severe (grade = 3) postoperative morbidity/mortality according to the Clavien-Dindo classification. Severe postoperative complication is defined by grade =III per-operative or post-operative complication occurring in the 30 days after surgery. up to 30 days after surgery
Secondary Rate of completion of full treatment without modification up to 58 days
Secondary Evaluation of the efficacy of both regimen in term of overall survival Overall survival using Kaplan-Meier method From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Secondary Evaluation of the efficacy of both regimen in term of disease-free survival Disease-free survival using Kaplan-Meier method From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
Secondary Evaluation of the safety of the evaluated regimens in terms of preoperative mortality. Preoperative mortality (grade 5) rate, according to NCI-CTCAE v4.0 criteria From registration to surgery
Secondary Evaluation of the safety of the evaluated regimens in terms of preoperative morbidities, postoperative morbidities, respiratory morbidities. Pre-operative morbidities according to NCI-CTCAE v4.0 criteria, post-operative morbidities occurring in the 30 days after surgery with the main post-operative complication graded according to Clavien-Dindo, post-operative morbidities occurring more than 30 days after surgery graded according to NCI-CTCAE V4.0, postoperative respiratory morbidity rate according to the Clavien-Dindo classification. From start of treatment to end of study
Secondary Evaluation of the efficacy of both regimen in term of Pathological response rate Complete pathological response (ypCR) rate Surgery
Secondary Evaluation of the efficacy of both regimen in term of quality of life Quality of life: QLQC30 and OES18 Up to 3 years after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05013697 - TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. Phase 2
Completed NCT02253602 - Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer N/A
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Completed NCT01900691 - Removal of the Evolution® Esophageal Stent - Fully Covered N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Terminated NCT01572987 - Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus N/A
Terminated NCT00760604 - A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer Phase 3
Completed NCT00160030 - Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer Phase 2
Suspended NCT00048529 - Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT02284802 - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy N/A
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Completed NCT05680077 - KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT03261947 - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Phase 2
Terminated NCT00094978 - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum Phase 1
Recruiting NCT02908204 - Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma N/A
Completed NCT02378948 - Nutritional Route In Esophageal Resection Trial II N/A
Completed NCT02703142 - Endoscopic Evaluation After Esophagectomy N/A
Recruiting NCT02604615 - The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Phase 3